Neurol. praxi. 2019;20(4):312-315 | DOI: 10.36290/neu.2019.134

Cortical inflammation in pathogenesis of multiple sclerosis

doc. MUDr. Vladimír Donáth, PhD.
II. neurologická klinika SZU, FNsP F. D. Roosevelta, Banská Bystrica

Multiple sclerosis is an autoimmune-related disease characterized by inflammation and neurodegeneration. Looking at inflammation,
its characteristics, intensity and localization has undergone changes in recent years. Acute and chronic inflammation
is present in all forms of SM. Cortical demyelination is an important pathological substrate for irreversible functional disability,
progression and cognitive impairment. A comprehensive understanding of inflammatory manifestations can help us to set up
individualized therapy for the patient.

Keywords: multiple sclerosis, acute and chronic inflammation, cortical demyelination

Published: September 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Donáth V. Cortical inflammation in pathogenesis of multiple sclerosis. Neurol. praxi. 2019;20(4):312-315. doi: 10.36290/neu.2019.134.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bjartman C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann-Neurol. 2000; 48: 893-901. doi:10.1002/1531-8294(200012)48:6<893::AID-ANA10>3.0CO,2-B. Go to original source...
    2. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1962; 25: 315-320. Go to original source... Go to PubMed...
    3. Frischer JM, Bramow S, Dal Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89. doi:10.1093/brain/awp070. Go to original source... Go to PubMed...
    4. Hauser S, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7): 676-688. Go to original source... Go to PubMed...
    5. Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017; 376: 221-234. Go to original source... Go to PubMed...
    6. Kidd D, Barkhof F, McConnel R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122(Pt1): 17-26. Go to original source... Go to PubMed...
    7. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(Pt 11): 2705-12. doi:10.1093/brain/awh641. Go to original source... Go to PubMed...
    8. Lassmann H, Bruck W, Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007; 17: 210-8. doi:10.1111/j.1750-3639.2007.00064x. Go to original source... Go to PubMed...
    9. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front. Immunol. 9: 3116. doi:10.3389/fimmu.2018.03116. Go to PubMed...
    10. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev. Neurol. 2016; 172(1): 3-13. Go to original source... Go to PubMed...
    11. Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, Reynolds R, O'Connor KC, Hafler DA. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011; 134: 534-41. Go to original source... Go to PubMed...
    12. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis. The 2013 revision. Neurology 2014; 83: 1-9. doi: 10.1212/WNL.0000000000000560. Go to original source... Go to PubMed...
    13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911. Go to original source... Go to PubMed...
    14. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47: 707-17. doi: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO,2-Q. Go to original source... Go to PubMed...
    15. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011; 365: 2188-97. doi:10.1056/NEJMoa1100648. Go to original source... Go to PubMed...
    16. Machado-Santos J, Saji E, Troscher A, Paunovic M, Liblau R, Gabriely G, Bien CG, Bauer J, Lassmann H. The compertmentalized inflammatory response in the multiple sclerosis brain is composed of tissue - resident CD8+ T lymphocytes and B cells. Brain 2018; 141: 2066-82. doi: 10.1093/brain/awy151. Go to original source... Go to PubMed...
    17. Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S, The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. Progress in neurobiology 2015; 127-128: 1-22. Go to original source... Go to PubMed...
    18. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017; 376: 209-220. Go to original source... Go to PubMed...
    19. Peterson JW, Bo L, Mark S, Chang A, Trapp BD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50(3): 389-400. Go to original source... Go to PubMed...
    20. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012; 12: 11. Go to original source... Go to PubMed...
    21. Popescu BFGh, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013; 19(4): 901-921. Go to original source... Go to PubMed...
    22. Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, Drulovic J, Filippi M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis a phase 2 study. Neurology 2014; 82: 573-81. Go to original source... Go to PubMed...
    23. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960-967. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.